Giuseppe Pontillo,Ferran Prados,Jordan Colman,Baris Kanber,Omar Abdel-Mannan,Sarmad Al-Araji,Barbara Ballenberg,Alessia Bianchi,Alvino Bisecco,Wallace Brownlee,Arturo Brunetti,Alessandro Cagol,Massimiliano Calabrese,Marco Castellaro,Ronja Christensen,Sirio Cocozza,Elisa Colato,Sara Collorone,Rosa Cortese,Nicola De Stefano,Christian Enzinger,Massimo Filippi,Michael A. Foster,Antonio Gallo,Claudio Gasperini,Gabriel Gonzalez-Escamilla,Cristina Granziera,Sergiu Groppa,Yael Hacohen,Hanne F. Harbo,Anna He,Einar A. Høgestøl,Jens Kuhle,Sara Llufriu,Carsten Lukas,Eloy Martinez-Heras,Silvia Messina,Marcello Moccia,Suraya Mohamud,Riccardo Nistri,Gro O. Nygaard,Jacqueline Palace,Maria Petracca,Daniela Pinter,Maria A. Rocca,Alex Rovira,Serena Ruggieri,Jaume Sastre-Garriga,Eva Strijbis,Ahmed Toosy,Tomas Uher,Paola Valsasina,Manuela Vaneckova,Hugo Vrenken,Jed Wingrove,Charmaine Yam,Menno M. Schoonheim,Olga Ciccarelli,James H. Cole,Frederik Barkhof,the MAGNIMS study group

Abstract:Disentangling brain ageing from disease-related neurodegeneration in patients with multiple sclerosis (PwMS) is increasingly topical. The brain-age paradigm offers a window into this problem but may miss disease-specific effects. Here, we statistically modelled disease duration (DD) in PwMS as a function of brain MRI scans and evaluated whether the brain-predicted DD gap (i.e., the difference between predicted and actual duration) could complement the brain-age gap as a DD-adjusted global measure of multiple sclerosis-specific brain damage. In this retrospective study, we used 3D T1-weighted brain MRI scans of PwMS (i) from a large multicentric dataset (n = 4,392) for age and DD modelling, and (ii) from a monocentric longitudinal cohort of patients with early multiple sclerosis (n = 252 patients, 749 sessions) for clinical validation. We trained and tested a deep learning model based on a 3D DenseNet architecture to predict DD from minimally pre-processed brain MRI scans, while age predictions were obtained with the previously validated DeepBrainNet algorithm. Model predictions were scrutinised to assess the influence of lesions and brain volumes, while the DD gap metric was biologically and clinically validated within a linear model framework assessing its relationship with brain-age gap values and with physical disability measured with the Expanded Disability Status Scale (EDSS). Our model predicted DD better than chance (mean absolute error = 5.63 years, R = 0.34) and was nearly orthogonal to the brain-age model, as suggested by the very weak correlation between DD gap and brain-age gap values ( = 0.06). DD predictions were influenced by spatially distributed variations in brain volume, and, unlike brain-predicted age, were sensitive to the presence of lesions (mean difference between unfilled and filled scans: 0.55 ± 0.57 years, < 0.001). The DD gap metric significantly explained EDSS scores (β = 0.060, < 0.001), adding to brain-age gap values (ΔR = 0.012, < 0.001). Longitudinally, increasing annualised DD gap was associated with greater annualised EDSS changes ( = 0.50, < 0.001), with a significant incremental contribution in explaining disability worsening compared to changes of the brain-age gap alone (ΔR = 0.064, < 0.001). The brain-predicted DD gap metric appears to be sensitive to multiple sclerosis-related lesions and brain atrophy, adding to the brain-age paradigm in explaining physical disability both cross-sectionally and longitudinally. Potentially, it may be used as a multiple sclerosis-specific biomarker of disease severity and progression.

Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis

Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders

Analysis and visualization of the effect of multiple sclerosis on biological brain age

Analysis of Brain Age Gap across Subject Cohorts and Prediction Model Architectures

Disentangling neurodegeneration from ageing in multiple sclerosis: the brain-predicted disease duration gap

BrainAgeNeXt: Advancing Brain Age Modeling for Individuals with Multiple Sclerosis

Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis

Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders

Brain MRI characteristics in neuromyelitis optica spectrum disorders: A large multi-center retrospective study in China

Advanced brain aging in multiple system atrophy compared to Parkinson's disease

Diagnostic accuracy of brain age prediction in a memory clinic population and comparison with clinically available volumetric measures

122. Assessment of Cognitive Function in Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD) Compared to Patients with Multiple Sclerosis

Predicting Brain Age Gap with Radiomics and AutoML: A Promising Approach for Age-Related Brain Degeneration Biomarkers

Cognitive function and brain magnetic resonance imaging profiles in neuromyelitis optica spectrum disorder and multiple sclerosis

Gray matter volume drives the brain age gap in schizophrenia: a SHAP study

Spatial Structural Abnormality Maps Associated with Cognitive and Physical Performance in Relapsing-Remitting Multiple Sclerosis

Discovery of High-Risk Clinical Factors That Accelerate Brain Aging in Adults: A Population-Based Machine Learning Study

Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning

Interpretable and Intuitive Machine Learning Approaches for Predicting Disability Progression in Relapsing-Remitting Multiple Sclerosis Based on Clinical and Gray Matter Atrophy Indicators

Visual Disability in Neuromyelitis Optica Spectrum Disorders: Prognostic Prediction Models

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study